| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fabb648be4bafcf594cc085f6a5495c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ef62dab972a92a0a27b4a0f9d7c0ce4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_430e5d6efda89fef52d5c43b394eeab4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f43b47abd136fee281c33fbedee3ae44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b9f62a24e6e696f537f299f8a50b59f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79fc0068abe35ae10f2ef15d2593c48a |
| publicationDate |
2019-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10342785-B2 |
| titleOfInvention |
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| abstract |
This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10973834-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021290641-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019314390-A1 |
| priorityDate |
2016-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |